GeneDx Holdings Corp. (NASDAQ:WGS) Major Shareholder Sells $1,317,377.92 in Stock

GeneDx Holdings Corp. (NASDAQ:WGSGet Free Report) major shareholder Opko Health, Inc. sold 39,824 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $33.08, for a total transaction of $1,317,377.92. Following the completion of the sale, the insider now directly owns 2,746,972 shares in the company, valued at approximately $90,869,833.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Opko Health, Inc. also recently made the following trade(s):

  • On Monday, August 19th, Opko Health, Inc. sold 50,000 shares of GeneDx stock. The shares were sold at an average price of $34.49, for a total transaction of $1,724,500.00.
  • On Monday, August 12th, Opko Health, Inc. sold 59,787 shares of GeneDx stock. The stock was sold at an average price of $33.95, for a total value of $2,029,768.65.
  • On Thursday, August 8th, Opko Health, Inc. sold 100,000 shares of GeneDx stock. The shares were sold at an average price of $31.82, for a total value of $3,182,000.00.
  • On Tuesday, August 6th, Opko Health, Inc. sold 12,994 shares of GeneDx stock. The stock was sold at an average price of $29.35, for a total value of $381,373.90.
  • On Wednesday, July 31st, Opko Health, Inc. sold 88,839 shares of GeneDx stock. The shares were sold at an average price of $33.50, for a total value of $2,976,106.50.
  • On Monday, July 29th, Opko Health, Inc. sold 50,000 shares of GeneDx stock. The stock was sold at an average price of $33.86, for a total transaction of $1,693,000.00.
  • On Friday, July 26th, Opko Health, Inc. sold 60,000 shares of GeneDx stock. The stock was sold at an average price of $33.85, for a total transaction of $2,031,000.00.
  • On Wednesday, July 24th, Opko Health, Inc. sold 75,000 shares of GeneDx stock. The stock was sold at an average price of $33.72, for a total transaction of $2,529,000.00.
  • On Monday, July 22nd, Opko Health, Inc. sold 50,000 shares of GeneDx stock. The stock was sold at an average price of $32.61, for a total value of $1,630,500.00.
  • On Friday, July 19th, Opko Health, Inc. sold 25,000 shares of GeneDx stock. The shares were sold at an average price of $32.29, for a total transaction of $807,250.00.

GeneDx Trading Up 2.8 %

Shares of NASDAQ WGS traded up $0.96 during midday trading on Monday, hitting $35.53. 551,751 shares of the company traded hands, compared to its average volume of 404,123. GeneDx Holdings Corp. has a 12-month low of $1.16 and a 12-month high of $37.45. The firm has a market cap of $928.11 million, a P/E ratio of -6.86 and a beta of 2.29. The stock has a 50-day moving average price of $30.31 and a 200 day moving average price of $18.71. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.99 and a current ratio of 2.38.

Analyst Ratings Changes

A number of equities analysts have commented on WGS shares. The Goldman Sachs Group lifted their price target on GeneDx from $28.00 to $32.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. TD Cowen increased their price target on shares of GeneDx from $46.00 to $50.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st. BTIG Research boosted their price objective on shares of GeneDx from $35.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st. Jefferies Financial Group initiated coverage on shares of GeneDx in a research note on Monday, June 3rd. They set a “hold” rating and a $21.00 price objective for the company. Finally, Craig Hallum raised their target price on GeneDx from $43.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $38.80.

View Our Latest Analysis on WGS

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC purchased a new position in shares of GeneDx in the 2nd quarter valued at approximately $34,000. nVerses Capital LLC purchased a new stake in shares of GeneDx in the 2nd quarter worth about $50,000. PFG Investments LLC bought a new position in shares of GeneDx in the 1st quarter worth about $95,000. The Manufacturers Life Insurance Company purchased a new position in GeneDx during the 2nd quarter valued at about $290,000. Finally, Algert Global LLC purchased a new stake in GeneDx in the second quarter worth about $356,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

About GeneDx

(Get Free Report)

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

Further Reading

Insider Buying and Selling by Quarter for GeneDx (NASDAQ:WGS)

Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.